Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
WaterBridge Q3 2026 net income totals $13.3 million; Q3 2026 revenue rises 17% year-over-year to $240.2 million

WaterBridge Q3 2026 net income totals $13.3 million; Q3 2026 revenue rises 17% year-over-year to $240.2 million

BitgetBitget2026/11/04 21:48
  • WaterBridge reported third-quarter 2026 net income of $13.3 million.
  • Revenue rose 17% year-over-year to $240.2 million, while produced water handling volumes increased 9% to 2,752,000 barrels per day.
  • Speedway Phase I outperformed expectations, supporting capital-efficient growth and demonstrating continued demand for long-haul produced water handling solutions.
  • Capital expenditure guidance for 2026 narrowed to $530 million–$560 million due to expected spending shifting into 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waterbridge Infrastructure LLC published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12